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Introduction 
ATI earlier report from this Centre (Tuber-
culosis Chemotherapy Centre, Madras, 1964) 
showed that a fully supervised twice-weekly 
regimen of streptomycin plus high-dosage 
isoniazid was highly effective in the treatment 
of patients with newly-diagnosed bacteriologi-
cally confirmed pulmonary tuberculosis. How-
ever, this regimen involves intramuscular 
injections of streptomycin and may not always 
be easy to organize, especially in rural areas 
and in developing countries with limited 
resources. For this reason, it was decided to 
investigate the possibility of replacing strepto-
mycin in the twice-weekly regimen by two oral 
drugs, namely ethionamide and PAS. Ethiona-
mide was chosen since, apart from isoniazid 
and streptomycin, it was the most potent drug 
available at the time, and PAS was included with 
a view to enhance the efficacy of the regimen. 
Finally, it was decided that the patients should 
be given an intensive phase of daily treatment 
with streptomycin, PAS and isoniazid for two 
weeks. 
Experiments in the guinea-pig had shown 
that the size of the individual dose of a drug 
needed to be increased as the interval between 
successive doses was increased (Dickinson & 
Mitchison, 1966). As PAS is bulky and the 
dosage of isoniazid in the twice-weekly regimen 
was already high, namely 15 mg./kg. body-
weight, it was decided to explore the possibility 
of increasing the dosage of ethionamide to a 
level higher than that usually employed (0.5— 
1.0 g.) in daily regimens. An investigation 
was therefore undertaken to determine the 
maximum tolerated dose of ethionamide. when 
administered twice-weekly together with isonia-
zid plus PAS. Since the assessment of ethio-
namide intolerance is largely subjective, the 
study was conducted ‘double-blind’ with respect 
to the dosage of ethionamide. 
Plan and conduct of the study 
The patients came from the poorest sections 
of the population of Madras City, were aged 
12 years or more and had newly-diagnosed 
* Deceased. 
bacteriologically confirmed   pulmonary 
tuberculosis. 
Treatment 
In the first two weeks, the patients received 
daily chemotherapy with streptomycin I g., 
sodium PAS 6 g. (in four cachets) and isoniazid 
400 mg. as a single tablet incorporating 
pyridoxine 6 mg. Subsequently,they received 
a twice-weekly regimen of sodium PAS 6 g., 
isoniazid 15 mg./kg. body-weight* (incorporat-
ing pyridoxine 6 mg.) and ethionamide in the 
dosage described below, all the drugs being 
administered at the same time in a single dose 
under the direct supervision of a nurse at the 
Centre. 
Plan of administration of ethionamide 
The prescription of ethionamide was made, 
in accordance with the plan below, by one of 
two physicians (‘prescribing’ physicians), 
neither of whom interviewed the patients after 
the commencement of treatment. 
Ethionamide was administered to the 
patients in cachets, each cachet containing 
either one or two uncrushed tablets of ethiona-
mide 0.25 g.; these cachets were identical in 
appearance to the cachets containing PAS. 
Short-term study 
To begin with, ethionamide was adminis-
tered in a dose of 0.5 g. on four occasions, 
together with isoniazid and PAS, at intervals 
of three and four days alternately. 
(A) If clear-cut intolerance (that is, in- 
tolerance warranting a modification of treat- 
ment) did not occur, the dose was increased by 
0.25g.; for the next four occasions. This pro-
cedure after every fourth dose until a dose of  
1.5 g. had been tolerated on  four consecutive 
occasions,   unless   clear-cut   intolerance   was 
reported. 
(B) If clear-cut intolerance to   any dose 
was observed, ethionamide was withdrawn, 
and 
* that is, 400 mg., 600 mg. and 750 mg. for 
patients weighing less than 30.0 kg., 30.0-44.9 kg. and 
45.0 kg. or more, respectively. 
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instead, an equal number of dummy cachets** 
was prescribed for two weeks, or longer if the 
toxic manifestations persisted. At the end of 
this period, ethionamide was reintroduced in 
the same dose and tentatively prescribed for 
four occasions. 
(1) If  clear-cut   intolerance   did   not   re- 
emerge, the dose of ethionamide was in- 
creased by 0.25 g. for the next four occasions, 
the subsequent management being as stated 
in (A) and (B). 
(2) If dear-cut intolerance did re-emerge, 
it was considered that the maximum tole- 
rated dose (defined below) had been esta- 
blished.   Ethionamide was withdrawn for 
two weeks (or longer if the toxic manifesta- 
tions persisted), and an equal number of 
dummy cachets prescribed.   At the end of 
this period, a longer-term study was com- 
menced. 
Definition of maximum tolerated dose of 
ethionamide 
The maximum tolerated dose of ethiona-
mide for a patient was defined as the highest 
dose of ethionamide (not exceeding 1.5 g.) 
tolerated twice-weekly for two weeks. 
Longer-term study 
Once the maximum tolerated dose of 
ethionamide was determined, the aim was to 
prescribe this dose for a period of eight weeks, 
in order to obtain information on longer-term 
tolerance. If clear-cut intolerance emerged at 
any time during the eight weeks, ethionamide 
was withdrawn and the patient prescribed 
dummy cachets for two weeks, or longer if the 
toxic manifestations persisted. At the end of 
this period, ethionamide was introduced in a 
dose which, was lower by 0.25 g, and prescribed 
for a period of eight weeks. This procedure was 
repeated, if necessary. 
Assessment of intolerance to ethionamide 
The assessment of intolerance lo ethiona-
mide was undertaken by three physicians 
(‘assessing’ physicians), who were unaware of 
** The dummy cachets, each containing a tablet 
of calcium gluconate 0,5 g., were identical in appear-
ance to those containing ethionamide. They were 
employed in order to conceal, both from the patient 
and the ‘assessing’ physicians that ethionamide        
was being withdrawn during this period. However,     
to reassure the patient that some action had been 
taken following the complaints of side-effects,          
one undisguised placebo tablet (calcium gluconate 
0.5 g.) was also administered with each dose. 
the plan of administration of ethionamide. In 
consequence, although they knew that the 
patients were attending the Centre twice a week 
to receive an ethionamide-containing regimen, 
they had no knowledge of the dose of ethiona-
mide received by any patient at any point in 
time during the study. 
At the start of treatment, the patients were 
allotted in equal numbers to the three assessing 
physicians. On all subsequent occasions, 
that is, (a) at monthly examinations, (b) after 
spontaneous complaints, and (c) after default 
from attendance, each patient was seen by his 
assessing physician. The patients were never 
questioned to elicit symptoms of intolerance to 
ethionamide. However, whenever a spontaneous 
complaint was made, the assessing physician      
interrogated the patient carefully and assessed 
the severity of the symptoms. If the symptoms 
were mild, he reassured the patient and per-
suaded him to continue the chemotherapy. If 
however, the symptoms were severe or persistent 
(clear-cut intolerance), he recommended a 
modification of treatment. The actual modi-
fication was made, in accordance with the       
design of the study, by one of the two pres-
cribing physicians. Autiemetic drugs, antihis-
mines and tranquilizers, which might have 
ameliorated the symptoms, were not prescribed. 
Results 
In all, 30 patients were admitted to the 
study. Of these, three stopped attending the 
Centre, because of domestic problems, before 
their maximum tolerated dose could be deter-
mined. Two were receiving 1.0 g, of ethiona-
mide and the third 0,75 g. at the time. There 
remain 27 patients (18 males, nine females) in 
the analysis. Of these, 15 were aged less than 
35 years, six were aged 35-44 years and six 
were aged 45 years or more. The weight was 
less than 30.0 kg. in two, 30.0—44.9 kg. in 19, 
and 45.0 kg. or more in the remaining six. 
Maximum tolerated dose of ethionamide 
Table 1 presents the distribution of patients 
according to the maximum dose tolerated on 
four consecutive occasions. Of the 27 patients, 
10 (37 per cent) tolerated the highest planned 
dose of 1.5 g., while three (11 per cent) tole-
rated 1.25 g. On the other hand, four (15          
per cent) tolerated only 0.5 g. and five (19 per 
cent) tolerated 0.75 g. but not more. When 
expressed as mg./kg. body-weight, the 
maximum tolerated dose was 40 mg./kg. or 
more for four (15 per cent) patients and 30-39 
mg./kg. for seven (26 per cent) ; however, it 
was 19 nig./kg. or less for seven (26 per cent) 
patients. 
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TABLE I 
Maximum tolerated dose of ethionamide 
 
 Maximum tolerated dose* (g.)  
Patients         
No.           % 
Maximum tolerated 
dose* (mg./kg.) 
Patients     
No.       %  
 0.50  4          15  10-19  7          26  
              0.75    5           19  20—29  9         33  
 1.00  5           19  30-39  7           26  
 1.25  3           11  40-49  4          15  
 1.50  10           37    
 Total  27          101  Total  27           100  
Complaints of ethionamide intolerance 
Of the 27 patients, 24 had complained of one 
or more symptoms of ethionamide intoler-        
ance before their maximum tolerated dose       
was established ; 18 patients complained of 
vomiting, 11 of giddiness, six of nausea, seven       
of anorexia and seven of abdominal pain.      
Of the 24 patients, 16 made the first com-   
plaint on the 0.5 g. dose, six on the 0.75 g. 
dose, one on the 1.0 g. dose and one on the       
1.25 g. dose. 
Number of weeks for which the maximum 
tolerated dose was received 
Once the maximum tolerated dose was 
determined, the aim was, as already stated, to 
prescribe it for a further period of eight weeks.      
In the event, this was not attempted for four 
patients (with maximum tolerated doses of        
0.5, 0.5, 0.75 and 1.0 g.), mainly because of          
non-cooperation induced by the occurence of 
ethionamide intolerance in the course of 
determining the maximum tolerated dose. 
Another patient, whose maximum tolerated     
dose was 1.0 g., developed peripheral neuro-  
pathy attributed to isoniazid and was with-  
drawn from the study. Of the remaining 22 
patients, only two, both with a maximum 
tolerated dose of 1.5 g., completed the 8-week 
period on this dose. Indeed, of the 20 patients   
who did not complete the 8-week period, 17 
developed clear-cut intolerance within two 
weeks, and remaining three in the third, the   
fifth and the seventh week. 
Tolerance, over an 8-week period,  of doses 
lower than the maximum tolerated dose 
It will be recalled that  if clear-cut intole- 
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rance to ethionamide developed during the       
8-week period, as it did in 20 patients, the 
dose was reduced in steps of 0.25 g. to deter-
mine whether the patient could tolerate a lower 
dose for eight weeks. In the event, only two 
patients, having maximum tolerated doses of 
1.5 g. and 1.25 g., completed eight weeks on a 
reduced dose, namely 1.25 g. and 0.75 g, 
respectively. The remaining 18 did not com-
plete eight  weeks on any one dose;  the 
last dose received was 0.5 g. for 10 patients, 
0.75 g. for three, 1.0 g. for three and 1.25 g. 
for two patients (Table II), It is of interest 
that of the 10 patients whose last dose was 
0.5 g., five had tolerated earlier, for two weeks, 
the highest planned dose, namely 1.5 g. 
When expressed as mg./kg. body-weight, 
the last dose received was less than 20 mg./kg. 
in 14 (78 per cent) of the 18 patients. In 
none of the patients was it 30 mg./kg. or more, 
although 6 (33 per cent) of them had earlier 
tolerated 30-45 mg./kg. for two weeks. 
Omission of PAS 
Since PAS, like ethionamide, is capable of 
producing gastro-intestinal side-effects, it was 
thought that its omission might result in higher 
values for the maximum tolerated dose of 
ethionamide. Consequently, a further group 
of 30 patients (18 males, 12 females) was in-
vestigated, the plan of the study being the same 
except that no PAS was prescribed. 
Of the 30 patients, one could not tolerate 
even 0.5 g. of ethionamide ; the maximum 
tolerared dose was 0.5 g. for seven patients, 
0.75 g, for two, 1.0 g. for four, 1.25 g. for 
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TAULE II 
Last dose of ethionamide received by patients who did not complete                         
eight weeks on any one dose 
 Maximum  tolerated dose* (g.)   
0.50       0.75  1.00 1.25 1 50
 
 Last  dose of    
ethionamide  
received (g.)  
 
 
Total 
patients  
     
0.50 
0.75 
1.00      
1. 25
10  
3 
3  
2
2  
0 
 1 
─
0  
0 
1 
1
5 
0 
1  
1
  
 
2             1 
             
─           3 
─          ─ 
─          ─ 
    
 
18        2           4         3     2  7  
 
Total  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
seven and 1.5 g, for nine patients. Thus, 
one-third of the patients (10 of 30) could not 
tote-rate even l.0g. ( i t  will be recalled that the 
corresponding proportion in patients who 
received PAS in addition to ethionamide and 
isoniazid was indentical, namely nine of 27). 
When these findings became known, the 
study of longer-term tolerance was 
terminated. 
Maximum tolerated dose of ethionamide 
related to sex, age and weight 
Since females have been reported to have a 
higher incidence of ethionamide side-effects 
than males (Verbist and others, 1967 ; Fox       
and others, 1969), the data were examined         
for the presence of an association between        
sex and the maximum tolerated dose in the      
57 patients reported in this paper. On aver-    
age, the maximum tolerated dose was 1.03 g. 
for 36 males compared with 1.14 g. for 21 
females, a non-significant difference (P=0.3). 
There was also no evidence that the 
maximum tolerated dose was influenced by 
either the age or the weight of the patient. 
Discussion 
The ‘double-blind’ investigation reported 
here was undertaken to determine the maximum 
dose of ethionamide that could be administered 
twice weekly to patients with newly-diagnosed 
bacteriologically confirmed pulmonary tuber-
culosis. The results are disappointing in that 
one-third of the patients could not tolerate      
even 1.0 g. of ethionamide twice-weekly for 
two weeks, when the drug was administered 
with isoniazid plus PAS or, indeed, with 
isoniazid alone. Moreover, of 22 patients      
who were prescribed their maximum tolerated 
dose (that is, the maximum dose tolerated on 
four consecutive occasions) for a period of 
eight weeks, 20 developed clear-cut intolerance 
during this period, 17 of them within two weeks. 
Indeed, nearly all had had symptoms of 
intolerance before they attained their maxi-
mum tolerated dose. These findings are 
discouraging for the long-term use of even a 
moderately high dosage of ethionamide on a 
twice-weekly basis in Madras patients. 
Fox and others (1969) studied, also in a 
‘double-blind’ investigation, acute intolerance 
to individual doses of ethionamide and prothio-
namide in East African patients who were    
under treatment with a daily regimen of 
isoniazid plus streptomycin. They concluded 
that in these patients, it would not be possible, 
as a routine, to increase the dosage of either 
ethionamide or prothionamide in intermittent 
regimens above the conventional dosages used 
in daily regimens. 
It has been reported by Prignot, Everaents 
and Tyberghein (1962) and Gyselen and others 
(1963) that vitamin B-complex preparations 
substantially reduce the frequency and severity 
of the side-effects of ethionamide. Later 
studies, however, have shown that this is not 
the case (Verbist and others, 1967 ; Fox and 
others, 1969). 
The design and conduct of this study merit 
special mention. The study was conducted 
‘double-blind’ with respect to ethionamide 
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maximum tolerated dose for a further period 
of eight weeks, only two completed the 8-week 
period on this dose; two more completed an  
8-week period on a reduced dose. 
The omission of PAS, in another group of 
30 patients, did not result in better tolerance of 
ethionamide, the number who failed to tolerate 
1.0 g. for two weeks being 10 (33 per cent). 
These findings are discouraging for the use 
of even a moderately high dosage of ethiona-
mide on a twice-weekly basis in Madras 
patients. 
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